INNO-LIA® ANA Update

One run to identify 13 autoantigens

INNO-LIA ANA Update is a line immunoassay for the detection and identification of autoantibodies against nuclear and cytoplasmic antigens in human serum.

      Contact sales for information
      CE marked (IVDR)
      INNO-LIA® ANA Update

      Product number 80320

      20 Tests
      Please contact your local Fujirebio representative for the availability of this product in your country.

      Click here to navigate

      • Contact sales for information
      • Details
      • Conditions of sale
      • Citations
      • Documentation
      • Product inquiry
      • Related products

      • Details

        Features & Benefits

        • Results for 13 antigens in one test run
        • Target specificity is 98% or more for all markers, combined with a high sensitivity
        • Visual interpretation or with scan software LiRAS® for LIA® ANA
        • Results within 3 hours
        • Fully automated processing of the strips possible using Auto-LIA™ 48

         
        Background

        Autoantibodies directed against distinct intracellular antigens can be detected in most of the systemic connective tissue diseases.

        Because characteristic profiles of autoantibodies are found in different diseases, determination of the specificity helps in establishing the correct diagnosis and facilitates the treatment and follow-up of the patient.

        Antibodies directed against antinuclear antibodies (ANA) are found in systemic connective tissue diseases.

        Some of these antibodies are very sensitive indicators of a certain disease, such as anti-RNP for mixed connective tissue disease (MCTD), but not specific.

        By contrast, other antibodies are more specific, such as anti-Sm in systemic lupus erythematosus (SLE), anti-Scl-70 in diffuse scleroderma, and anti-Jo-1 in polymyositis or dermatomyositis (PM/DM).

        In Sjögren's syndrome (SjS), no autoantibody is specific for the disease, but anti-SSA and anti-SSB show the best correlation.

        Also patients with SjS, secondary to SLE and rheumatoid arthritis (RA), show autoantibodies to SSA and SSB.

        The presence of mainly SSA antibodies during pregnancy has been associated with the development of congenital heart block in neonates.

        Patients with neurological complications to SLE may show ribosomal antibodies.

      • Conditions of sale

        To read the end user conditions of sale for this product please visit our Resource center.

      • Citations

      • Product inquiry

        CAPTCHA

        The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

        For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

        If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

      Veuillez confirmer que vous êtes un professionnel de la santé

      Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

      Choose your country or region

      Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
      The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.